Evidence map›Paper›PMID 34107889›Full record

ArticleBMC infectious diseases2021

Prospective Assessment of SARS-CoV-2 Seroconversion (PASS) study: an observational cohort study of SARS-CoV-2 infection and vaccination in healthcare workers.

Belinda M Jackson-Thompson, Emilie Goguet, Eric D Laing, Cara H Olsen, Simon Pollett, K Monique Hollis-Perry, Santina E Maiolatesi, Luca Illinik, Kathleen F Ramsey, Anatalio E Reyes and 22 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07287137 (IDCRP-154), which is not on this map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07287137 phase4active not recruitingnot on this mapstarted 2025, after this paper: background citation

IDCRP-154: Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study

TypeinterventionalSponsorHenry M. Jackson Foundation for the Advancement of Military MedicineRan2025 to 2027Enrolled54ConditionsCOVID -19, COVID - 19, COVID 19, InfluenzaArmsPfizer-BioNTech mRNA COVID-19 vaccine, Novavax recombinant protein vaccine
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Observational
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors at 5 institutions in 1 country.

Belinda M Jackson-ThompsonDepartment of Microbiology and Immunology, Uniformed Services University of the Health Science, Bethesda, MD, USA. Belinda.Jackson.ctr@usuhs.edu.ORCID http://orcid.org/0000-0002-5824-4986
Emilie GoguetDepartment of Microbiology and Immunology, Uniformed Services University of the Health Science, Bethesda, MD, USA.
Eric D LaingDepartment of Microbiology and Immunology, Uniformed Services University of the Health Science, Bethesda, MD, USA.
Cara H OlsenDepartment of Preventive Medicine & Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, USA.
Simon PollettHenry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, MD, USA.
K Monique Hollis-PerryClinical Trials Center, Naval Medical Research Center, Silver Spring, MD, USA.
Santina E MaiolatesiHenry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, MD, USA.
Luca IllinikHenry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, MD, USA.
Kathleen F RamseyClinical Trials Center, Naval Medical Research Center, Silver Spring, MD, USA.
Anatalio E ReyesClinical Trials Center, Naval Medical Research Center, Silver Spring, MD, USA.
Yolanda AlcortaClinical Trials Center, Naval Medical Research Center, Silver Spring, MD, USA.
Mimi A WongClinical Trials Center, Naval Medical Research Center, Silver Spring, MD, USA.
Julian DaviesHenry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, MD, USA.
Orlando OrtegaHenry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, MD, USA.
Edward ParmeleeInfectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Alyssa R LindroseDepartment of Microbiology and Immunology, Uniformed Services University of the Health Science, Bethesda, MD, USA.
Matthew MoserDepartment of Microbiology and Immunology, Uniformed Services University of the Health Science, Bethesda, MD, USA.
Elizabeth GraydonDepartment of Microbiology and Immunology, Uniformed Services University of the Health Science, Bethesda, MD, USA.
Andrew G LetiziaInfectious Disease Directorate, Naval Medical Research Center, Silver Spring, MD, USA.
Christopher A DuplessisClinical Trials Center, Naval Medical Research Center, Silver Spring, MD, USA.
Anuradha GanesanHenry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, MD, USA.
Kathleen P PrattDepartment of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Allison M MalloyDepartment of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
David W ScottDepartment of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Stephen K AndersonBasic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Andrew L SnowDepartment of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Clifton L DalgardDepartment of Anatomy, Physiology, and Genetics, and The American Genome Center, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
John H PowersClinical Research Directorate, Leidos Biomedical Research, Inc, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
David TribbleInfectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Timothy H BurgessInfectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Christopher C BroderDepartment of Microbiology and Immunology, Uniformed Services University of the Health Science, Bethesda, MD, USA.
Edward MitreDepartment of Microbiology and Immunology, Uniformed Services University of the Health Science, Bethesda, MD, USA. Edward.Mitre@usuhs.edu.
Uniformed Services University of the Health Sciences · USHenry M. Jackson Foundation · USNaval Medical Research Command · USFrederick National Laboratory for Cancer Research · USLeidos (United States) · US

Funding

CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001E
6 · The paper itself

Abstract

backgroundSARS-CoV-2 is a recently emerged pandemic coronavirus (CoV) capable of causing severe respiratory illness. However, a significant number of infected people present as asymptomatic or pauci-symptomatic. In this prospective assessment of at-risk healthcare workers (HCWs) we seek to determine whether pre-existing antibody or T cell responses to previous seasonal human coronavirus (HCoV) infections affect immunological or clinical responses to SARS-CoV-2 infection or vaccination.

methodsA cohort of 300 healthcare workers, confirmed negative for SARS-CoV-2 exposure upon study entry, will be followed for up to 1 year with monthly serology analysis of IgM and IgG antibodies against the spike proteins of SARS-CoV-2 and the four major seasonal human coronavirus - HCoV-OC43, HCoV-HKU1, HCoV-229E, and HCoV-NL63. Participants will complete monthly questionnaires that ask about Coronavirus Disease 2019 (COVID-19) exposure risks, and a standardized, validated symptom questionnaire (scoring viral respiratory disease symptoms, intensity and severity) at least twice monthly and any day when any symptoms manifest. SARS-CoV-2 PCR testing will be performed any time participants develop symptoms consistent with COVID-19. For those individuals that seroconvert and/or test positive by SARS-CoV-2 PCR, or receive the SARS-CoV-2 vaccine, additional studies of T cell activation and cytokine production in response to SARS-CoV-2 peptide pools and analysis of Natural Killer cell numbers and function will be conducted on that participant's cryopreserved baseline peripheral blood mononuclear cells (PBMCs). Following the first year of this study we will further analyze those participants having tested positive for COVID-19, and/or having received an authorized/licensed SARS-CoV-2 vaccine, quarterly (year 2) and semi-annually (years 3 and 4) to investigate immune response longevity. DISCUSSION: This study will determine the frequency of asymptomatic and pauci-symptomatic SARS-CoV-2 infection in a cohort of at-risk healthcare workers. Baseline and longitudinal assays will determine the frequency and magnitude of anti-spike glycoprotein antibodies to the seasonal HCoV-OC43, HCoV-HKU1, HCoV-229E, and HCoV-NL63, and may inform whether pre-existing antibodies to these human coronaviruses are associated with altered COVID-19 disease course. Finally, this study will evaluate whether pre-existing immune responses to seasonal HCoVs affect the magnitude and duration of antibody and T cell responses to SARS-CoV-2 vaccination, adjusting for demographic covariates.

Indexed as

SeroconversionAntibodies, ViralAsymptomatic InfectionsCoronavirusCOVID-19COVID-19 VaccinesCross ReactionsHealth PersonnelHumansProspective StudiesSARS-CoV-2Spike Glycoprotein, CoronavirusT-LymphocytesVaccinationAntibodies, ViralCOVID-19 VaccinesSpike Glycoprotein, CoronavirusCoronavirusCOVID-19Cross-reactivityImmune-responseProspective studySARS-CoV-2

Identifiers

PMID34107889
PMCPMC8188741
OpenAlexW3172284335

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.